Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

vTv Therapeutics (VTVT) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for vTv Therapeutics (VTVT) over the last 12 years, with Q3 2025 value amounting to $4.6 million.

  • vTv Therapeutics' Change in Accured Expenses rose 91185.84% to $4.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.6 million, marking a year-over-year increase of 20655.35%. This contributed to the annual value of -$5.2 million for FY2024, which is 27804.71% down from last year.
  • Latest data reveals that vTv Therapeutics reported Change in Accured Expenses of $4.6 million as of Q3 2025, which was up 91185.84% from $1.0 million recorded in Q2 2025.
  • In the past 5 years, vTv Therapeutics' Change in Accured Expenses registered a high of $4.6 million during Q3 2025, and its lowest value of -$3.0 million during Q3 2022.
  • For the 5-year period, vTv Therapeutics' Change in Accured Expenses averaged around $182210.5, with its median value being -$129000.0 (2021).
  • Per our database at Business Quant, vTv Therapeutics' Change in Accured Expenses plummeted by 214341.09% in 2022 and then soared by 91185.84% in 2025.
  • Quarter analysis of 5 years shows vTv Therapeutics' Change in Accured Expenses stood at $3.3 million in 2021, then crashed by 83.21% to $561000.0 in 2022, then grew by 17.47% to $659000.0 in 2023, then crashed by 281.94% to -$1.2 million in 2024, then soared by 482.57% to $4.6 million in 2025.
  • Its last three reported values are $4.6 million in Q3 2025, $1.0 million for Q2 2025, and -$836000.0 during Q1 2025.